▲ Peaking
Business
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
CSL has entered a global partnership with Swiss firm Alentis worth up to $1.6 billion to co-develop a phase 2-stage fibrosis drug.
Fibrosis
1 trends tracked about this subject — the full history, oldest to newest below.